File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Compatibility of multiple herbal components in Erxian Decoction, a Chinese medicinal formula, for treating osteoporosis

TitleCompatibility of multiple herbal components in Erxian Decoction, a Chinese medicinal formula, for treating osteoporosis
Authors
KeywordsChinese medicines
Erxian Decoction
Menopause
Osteoporosis
Issue Date2012
Citation
European Journal Of Integrative Medicine, 2012, v. 4 n. 2, p. e187-e196 How to Cite?
AbstractIntroduction: Estrogen deficiency during menopause would increase the risk of osteoporosis. Erxian Decoction (EXD), an anti-menopausal Chinese medicinal formula with anti-osteoporotic effect, appears to be an attractive alternative for treating menopausal osteoporosis. However, the drug compatibility of component herbs in EXD according to traditional Chinese medicine theory has not been explored. In this study, the drug compatibility of EXD according to the organizing principle of Chinese medicinal formula was investigated, using anti-osteoporotic properties as a study model. Methodology: Proliferation of RAW 264.7 osteoclast precursor cells and hFOB 1.19 human fetal osteoblasts was determined by MTT assay. Osteoclastogenesis of RAW 264.7 cells was assessed by tartrate-resistant acid phosphatase (TRAP) staining. Osteoprotegerin secretion from hFOB 1.19 cells was determined by ELISA. The protein levels of NF-κB, IκB, c-Fos and NFATc1 involved in osteoclastogenesis were studied by immunoblotting analysis. Results: EXD inhibited the proliferation of RAW 264.7 cells while it stimulated the proliferation of hFOB 1.19 cells, which was mainly mediated by the Monarch herb (. Herba Epimedii) and the Minister herbs (. Radix Morindae officinalis) respectively. EXD also stimulated secretion of osteoprotegerin from hFOB 1.19 cells. EXD exerted an inhibitory effect on the differentiation of RAW 264.7 cells into mature osteoclast, as revealed in TRAP staining, which was probably mediated by the Assistant herb (. Cortex Phellodendri) through down-regulation of NFATc1 protein. Conclusions: EXD inhibited proliferation and differentiation of osteoclast precursor cells, while it stimulated proliferation of osteoblasts and osteoprotegerin secretion. The drug compatibility of EXD according to Chinese medicine theory was also demonstrated. © 2012 Elsevier GmbH.
Persistent Identifierhttp://hdl.handle.net/10722/166086
ISSN
2015 Impact Factor: 0.769
2015 SCImago Journal Rankings: 0.269
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorSze, SCWen_HK
dc.contributor.authorIp, CWen_HK
dc.contributor.authorNg, TBen_HK
dc.contributor.authorZhang, KYen_HK
dc.contributor.authorZhang, ZJen_HK
dc.contributor.authorCheung, HPen_HK
dc.contributor.authorCheng, CLYen_HK
dc.contributor.authorTong, Yen_HK
dc.date.accessioned2012-09-20T08:27:57Z-
dc.date.available2012-09-20T08:27:57Z-
dc.date.issued2012en_HK
dc.identifier.citationEuropean Journal Of Integrative Medicine, 2012, v. 4 n. 2, p. e187-e196en_HK
dc.identifier.issn1876-3820en_HK
dc.identifier.urihttp://hdl.handle.net/10722/166086-
dc.description.abstractIntroduction: Estrogen deficiency during menopause would increase the risk of osteoporosis. Erxian Decoction (EXD), an anti-menopausal Chinese medicinal formula with anti-osteoporotic effect, appears to be an attractive alternative for treating menopausal osteoporosis. However, the drug compatibility of component herbs in EXD according to traditional Chinese medicine theory has not been explored. In this study, the drug compatibility of EXD according to the organizing principle of Chinese medicinal formula was investigated, using anti-osteoporotic properties as a study model. Methodology: Proliferation of RAW 264.7 osteoclast precursor cells and hFOB 1.19 human fetal osteoblasts was determined by MTT assay. Osteoclastogenesis of RAW 264.7 cells was assessed by tartrate-resistant acid phosphatase (TRAP) staining. Osteoprotegerin secretion from hFOB 1.19 cells was determined by ELISA. The protein levels of NF-κB, IκB, c-Fos and NFATc1 involved in osteoclastogenesis were studied by immunoblotting analysis. Results: EXD inhibited the proliferation of RAW 264.7 cells while it stimulated the proliferation of hFOB 1.19 cells, which was mainly mediated by the Monarch herb (. Herba Epimedii) and the Minister herbs (. Radix Morindae officinalis) respectively. EXD also stimulated secretion of osteoprotegerin from hFOB 1.19 cells. EXD exerted an inhibitory effect on the differentiation of RAW 264.7 cells into mature osteoclast, as revealed in TRAP staining, which was probably mediated by the Assistant herb (. Cortex Phellodendri) through down-regulation of NFATc1 protein. Conclusions: EXD inhibited proliferation and differentiation of osteoclast precursor cells, while it stimulated proliferation of osteoblasts and osteoprotegerin secretion. The drug compatibility of EXD according to Chinese medicine theory was also demonstrated. © 2012 Elsevier GmbH.en_HK
dc.languageengen_US
dc.relation.ispartofEuropean Journal of Integrative Medicineen_HK
dc.subjectChinese medicinesen_HK
dc.subjectErxian Decoctionen_HK
dc.subjectMenopauseen_HK
dc.subjectOsteoporosisen_HK
dc.titleCompatibility of multiple herbal components in Erxian Decoction, a Chinese medicinal formula, for treating osteoporosisen_HK
dc.typeArticleen_HK
dc.identifier.emailSze, SCW: stephens@hku.hken_HK
dc.identifier.emailZhang, KY: ybzhang@hku.hken_HK
dc.identifier.emailZhang, ZJ: zhangzj@hkucc.hku.hken_HK
dc.identifier.emailTong, Y: tongyao@hku.hken_HK
dc.identifier.authoritySze, SCW=rp00514en_HK
dc.identifier.authorityZhang, KY=rp01410en_HK
dc.identifier.authorityZhang, ZJ=rp01297en_HK
dc.identifier.authorityTong, Y=rp00509en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.eujim.2012.01.006en_HK
dc.identifier.scopuseid_2-s2.0-84862777533en_HK
dc.identifier.hkuros209476en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84862777533&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume4en_HK
dc.identifier.issue2en_HK
dc.identifier.spagee187en_HK
dc.identifier.epagee196en_HK
dc.identifier.isiWOS:000304259500009-
dc.identifier.scopusauthoridSze, SCW=23482617000en_HK
dc.identifier.scopusauthoridIp, CW=55261841800en_HK
dc.identifier.scopusauthoridNg, TB=35311803300en_HK
dc.identifier.scopusauthoridZhang, KY=23483121900en_HK
dc.identifier.scopusauthoridZhang, ZJ=8061473900en_HK
dc.identifier.scopusauthoridCheung, HP=37033470100en_HK
dc.identifier.scopusauthoridCheng, CLY=55261326200en_HK
dc.identifier.scopusauthoridTong, Y=9045384000en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats